Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan and Abbott: it's still on

This article was originally published in Scrip

Executive Summary

Mylan and Abbott have tweaked the terms of the deal under which Mylan will acquire part of Abbott's generic drugs business. The move is likely a response to the US government's adjustment of its tax laws to make "inversion" deals less attractive, and signals that the deal is going ahead. The US move, made in September (scripintelligence.com, 23 September 2014), led to the collapse of AbbVie's bid for Shire last week (scripintelligence.com, 16 October 2014).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel